Compare BENF & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BENF | BEAT |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | 55 | 16 |
| Industry | Blank Checks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.6M | 48.9M |
| IPO Year | N/A | N/A |
| Metric | BENF | BEAT |
|---|---|---|
| Price | $3.25 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 24.5K | ★ 1.2M |
| Earning Date | 02-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.01 | $315.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.54 |
| 52 Week High | $9.96 | $4.00 |
| Indicator | BENF | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 49.69 |
| Support Level | $3.15 | $0.91 |
| Resistance Level | $3.56 | $1.28 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 39.53 | 53.85 |
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.